NCT02357238

Brief Summary

In order to improve the investigators knowledge about uveitis and the underlying mechanism of disease, the investigators propose collecting blood from patients with uveitis, isolating DNA and sequencing the DNA to identify genetic mutations or associations in these patients.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for all trials

Timeline
43mo left

Started Jan 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Jan 2011Jan 2030

Study Start

First participant enrolled

January 1, 2011

Completed
4.1 years until next milestone

First Submitted

Initial submission to the registry

February 3, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 6, 2015

Completed
14.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2030

Last Updated

March 4, 2026

Status Verified

March 1, 2026

Enrollment Period

19 years

First QC Date

February 3, 2015

Last Update Submit

March 2, 2026

Conditions

UveitisInfectious Uveitis

Keywords

UveitisInfectious

Outcome Measures

Primary Outcomes (1)

  • Non infectious uveitis

    Distinct uveitis conditions will have a polymorphism association or specific mutation.

    5 years

Secondary Outcomes (1)

  • Infectious uveitis

    5 years

Study Arms (1)

Uveitis

Uveitis or infectious uveitis patients

Eligibility Criteria

Age6 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Any patient able to sign an informed consent or child of age 6 with parental /guardian consent with the diagnosis of uveitis or infectious uveitis.

You may qualify if:

  • Any patient above with the diagnosis of uveitis.
  • Any patient with a diagnosis of infectious uveitis such as toxoplasmosis retinochoroiditis, herpes associated retinitis.

You may not qualify if:

  • Patients who are unable to give consent
  • Patients in whom an adequated blood sample can not be obtained.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood serum will be collected

MeSH Terms

Conditions

UveitisCommunicable Diseases

Condition Hierarchy (Ancestors)

Uveal DiseasesEye DiseasesInfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Sunil K. Srivastava, M.D.

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kimberly M Baynes, BSN, RN, COA

CONTACT

216-444-2566baynesk@ccf.org

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Staff physician

Study Record Dates

First Submitted

February 3, 2015

First Posted

February 6, 2015

Study Start

January 1, 2011

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2030

Last Updated

March 4, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)